Abstract:
The present invention provides a novel cancer marker that is useful in the diagnosis of urothelial cancer. The present invention uses ubiquilin 2 as a cancer marker for urothelial cancer (renal pelvis cancer, ureteral cancer, and bladder cancer). Detection of ubiquilin 2 in a urine sample allows easy and accurate diagnosis of a possibility of urothelial cancer. The present invention is also applicable to the diagnosis of squamous cancer (esophageal cancer, cervical cancer, etc.).
Abstract:
A non-transitory computer-readable recording medium storing a computer program, the computer program comprising: a selecting module configured to select, from among a plurality of biopotential signals, a biopotential signal containing a high proportion of a maternal cardiac potential signal component; an independent component analysis module configured to perform independent component analysis on the plurality of biopotential signals; a periodic signal detection module configured to detect, as a first peak time signal, a signal having periodic peaks from a biopotential signal and to detect, as second peak time signals, one or more signals having periodic peaks among signals output from the independent component analysis module; and an output signal selecting module configured to select from among the one or more second peak time signals a signal having peak times different from those of the first peak time signal.
Abstract:
A non-transitory computer-readable recording medium storing a computer program, the computer program comprising: a selecting module configured to select, from among a plurality of biopotential signals, a biopotential signal containing a high proportion of a maternal cardiac potential signal component; an independent component analysis module configured to perform independent component analysis on the plurality of biopotential signals; a periodic signal detection module configured to detect, as a first peak time signal, a signal having periodic peaks from a biopotential signal and to detect, as second peak time signals, one or more signals having periodic peaks among signals output from the independent component analysis module; and an output signal selecting module configured to select from among the one or more second peak time signals a signal having peak times different from those of the first peak time signal.
Abstract:
A first calculation unit receives phase characteristics Pa(f) and Pb(f) outputted from frequency transform units, calculates a propagation time difference based on a phase difference between the two phase characteristics in a high-frequency component thereof, and calculates a pulse wave velocity by dividing a difference in the distances of vascular pathways from the heart to respective measurement areas. Meanwhile, a second calculation unit calculates a pulse wave velocity by dividing the stated difference in the distances by a appearance time difference at a predetermined position in respective pulse waveforms obtained by rendering the measurement signals Pa(t) and Pb(t) on a time axis. A comparison unit compares the pulse wave velocities, and in the case where the ratio thereof is outside a predetermined range, an evaluation result indicating that it is possible that a predetermined pathologic change is present in the vascular pathway is outputted to a display processing unit.